vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and BRC Group Holdings, Inc. (RILY). Click either name above to swap in a different company.
Axsome Therapeutics, Inc. is the larger business by last-quarter revenue ($196.0M vs $188.3M, roughly 1.0× BRC Group Holdings, Inc.). BRC Group Holdings, Inc. runs the higher net margin — 47.9% vs -14.6%, a 62.5% gap on every dollar of revenue. On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (65.0% vs -21.9%). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (61.7% CAGR vs -15.4%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
AXSM vs RILY — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $196.0M | $188.3M |
| Net Profit | $-28.6M | $90.3M |
| Gross Margin | — | 79.5% |
| Operating Margin | -13.8% | 32.3% |
| Net Margin | -14.6% | 47.9% |
| Revenue YoY | 65.0% | -21.9% |
| Net Profit YoY | 61.9% | 1710.8% |
| EPS (diluted) | $-0.55 | $2.78 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $196.0M | $188.3M | ||
| Q3 25 | $171.0M | $215.3M | ||
| Q2 25 | $150.0M | $188.2M | ||
| Q1 25 | $121.5M | $197.2M | ||
| Q4 24 | $118.8M | $241.0M | ||
| Q3 24 | $104.8M | $225.5M | ||
| Q2 24 | $87.2M | $256.0M | ||
| Q1 24 | $75.0M | $263.4M |
| Q4 25 | $-28.6M | $90.3M | ||
| Q3 25 | $-47.2M | $91.1M | ||
| Q2 25 | $-48.0M | $139.5M | ||
| Q1 25 | $-59.4M | $-10.0M | ||
| Q4 24 | $-74.9M | $-5.6M | ||
| Q3 24 | $-64.6M | $-284.4M | ||
| Q2 24 | $-79.3M | $-433.6M | ||
| Q1 24 | $-68.4M | $-49.2M |
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 83.7% | ||
| Q2 25 | — | 81.3% | ||
| Q1 25 | — | 81.4% | ||
| Q4 24 | — | 79.8% | ||
| Q3 24 | — | 82.1% | ||
| Q2 24 | — | 84.5% | ||
| Q1 24 | — | 85.3% |
| Q4 25 | -13.8% | 32.3% | ||
| Q3 25 | -27.0% | 30.4% | ||
| Q2 25 | -24.5% | 5.7% | ||
| Q1 25 | -46.9% | -31.2% | ||
| Q4 24 | -61.1% | -69.2% | ||
| Q3 24 | -59.8% | -36.4% | ||
| Q2 24 | -89.5% | -90.8% | ||
| Q1 24 | -89.7% | -6.1% |
| Q4 25 | -14.6% | 47.9% | ||
| Q3 25 | -27.6% | 42.3% | ||
| Q2 25 | -32.0% | 74.1% | ||
| Q1 25 | -48.9% | -5.1% | ||
| Q4 24 | -63.1% | -2.3% | ||
| Q3 24 | -61.7% | -126.1% | ||
| Q2 24 | -91.0% | -169.4% | ||
| Q1 24 | -91.1% | -18.7% |
| Q4 25 | $-0.55 | $2.78 | ||
| Q3 25 | $-0.94 | $2.91 | ||
| Q2 25 | $-0.97 | $4.50 | ||
| Q1 25 | $-1.22 | $-0.39 | ||
| Q4 24 | $-1.54 | $-0.01 | ||
| Q3 24 | $-1.34 | $-9.39 | ||
| Q2 24 | $-1.67 | $-14.35 | ||
| Q1 24 | $-1.44 | $-1.71 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $322.9M | $226.6M |
| Total DebtLower is stronger | — | $1.4B |
| Stockholders' EquityBook value | $88.3M | $-171.5M |
| Total Assets | $689.8M | $1.7B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $322.9M | $226.6M | ||
| Q3 25 | $325.3M | $184.2M | ||
| Q2 25 | $303.0M | $267.4M | ||
| Q1 25 | $300.9M | $138.3M | ||
| Q4 24 | $315.4M | $146.9M | ||
| Q3 24 | $327.3M | $159.2M | ||
| Q2 24 | $315.7M | $236.9M | ||
| Q1 24 | $331.4M | $190.7M |
| Q4 25 | — | $1.4B | ||
| Q3 25 | — | $1.3B | ||
| Q2 25 | — | $1.3B | ||
| Q1 25 | — | $1.4B | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $88.3M | $-171.5M | ||
| Q3 25 | $73.7M | $-260.5M | ||
| Q2 25 | $73.1M | $-351.7M | ||
| Q1 25 | $53.2M | $-496.8M | ||
| Q4 24 | $57.0M | $-488.2M | ||
| Q3 24 | $92.9M | $-497.6M | ||
| Q2 24 | $102.9M | $-218.3M | ||
| Q1 24 | $144.0M | $228.4M |
| Q4 25 | $689.8M | $1.7B | ||
| Q3 25 | $669.3M | $1.7B | ||
| Q2 25 | $639.8M | $1.5B | ||
| Q1 25 | $596.7M | $1.5B | ||
| Q4 24 | $568.5M | $1.8B | ||
| Q3 24 | $561.5M | $2.2B | ||
| Q2 24 | $548.2M | $3.2B | ||
| Q1 24 | $545.7M | $5.0B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-18.7M | $26.2M |
| Free Cash FlowOCF − Capex | $-18.7M | — |
| FCF MarginFCF / Revenue | -9.6% | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | 0.29× |
| TTM Free Cash FlowTrailing 4 quarters | $-93.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-18.7M | $26.2M | ||
| Q3 25 | $1.0M | $-60.6M | ||
| Q2 25 | $-32.4M | $-25.6M | ||
| Q1 25 | $-43.4M | $184.0K | ||
| Q4 24 | $-26.2M | $-2.7M | ||
| Q3 24 | $-18.6M | $19.5M | ||
| Q2 24 | $-30.1M | $111.5M | ||
| Q1 24 | $-53.5M | $135.4M |
| Q4 25 | $-18.7M | — | ||
| Q3 25 | $988.0K | — | ||
| Q2 25 | $-32.4M | — | ||
| Q1 25 | $-43.7M | — | ||
| Q4 24 | $-26.2M | — | ||
| Q3 24 | $-18.7M | — | ||
| Q2 24 | $-30.2M | — | ||
| Q1 24 | $-53.6M | — |
| Q4 25 | -9.6% | — | ||
| Q3 25 | 0.6% | — | ||
| Q2 25 | -21.6% | — | ||
| Q1 25 | -36.0% | — | ||
| Q4 24 | -22.1% | — | ||
| Q3 24 | -17.9% | — | ||
| Q2 24 | -34.6% | — | ||
| Q1 24 | -71.4% | — |
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.3% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.1% | — | ||
| Q2 24 | 0.1% | — | ||
| Q1 24 | 0.1% | — |
| Q4 25 | — | 0.29× | ||
| Q3 25 | — | -0.66× | ||
| Q2 25 | — | -0.18× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXSM
Segment breakdown not available.
RILY
| Transferred At Point In Time | $101.4M | 54% |
| Wealth Management Segment | $30.7M | 16% |
| Corporate Finance Consulting And Investment Banking Fees | $27.1M | 14% |
| Services And Fees | $24.8M | 13% |
| Commissions Fees And Reimbursed Expenses | $4.8M | 3% |
